Key result
Astaxanthin supplementation (12 mg/day) will be evaluated against placebo for its effects on arterial stiffness, oxidative stress, and inflammation in a planned randomized controlled trial of 66 renal transplant recipients over one year.
Why the study?
Does astaxanthin improve arterial stiffness, oxidative stress, and inflammation in renal transplant patients?
Population
66 renal transplant recipients, age > 18 and < 85 years. Exclusions: already taking antioxidant…
Comparison
Astaxanthin 12 mg/day oral for one year. vs Identical matching placebo for one year.
Design
RCT, Computer generated random numbers placed in blocks of ten by an…
Follow-up
12 months
Authors
Loading...
Planned RCT will test astaxanthin for vascular and inflammatory benefits in renal transplant recipients; leaves open efficacy until completion.
RCT (n=66)
Double-blind
Computer generated random numbers
Yes
Does astaxanthin improve arterial stiffness, oxidative stress, and inflammation in renal transplant patients?
This study protocol outlines a randomized controlled trial to evaluate whether astaxanthin supplementation can reduce arterial stiffness, oxidative stress, and inflammation in renal transplant recipients.
Fassett et al. (2008) conducted an RCT in Renal transplant (n=66). Astaxanthin vs. Placebo was evaluated on Changes in arterial stiffness (aortic pulse wave velocity), oxidative stress (plasma isoprostanes), and inflammation (plasma pentraxin 3). Astaxanthin supplementation (12 mg/day) will be evaluated against placebo for its effects on arterial stiffness, oxidative stress, and inflammation in a planned randomized controlled trial of 66 renal transplant recipients over one year.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: